Advantages and Disadvantages of Car-T Therapy in the Clinical Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Kaiyuan Guo

doi:10.54097/hset.v36i.5685

Authors

Kaiyuan Guo

DOI:

https://doi.org/10.54097/hset.v36i.5685

Keywords:

Car-T Therapy, Diffuse Large B-Cell Lymphoma, Clinical Trial.

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy is a new innovative cancer treatment. In recent years, many clinical studies have demonstrated its efficacy in the treatment of DLBCL. Compared to many existing cancer treatments, CAR-T therapy offers many advantages. For example, unique specificity and excellent efficacy in patients with refractory and recurrent tumors. This article focuses on the application of CAR-T in the treatment of DLBCL and analyzes the advantages and disadvantages of this therapy from multiple perspectives. The advantages of CAR-T therapy are discussed in three aspects: CAR-T for relapsed and chemotherapy-resistant patients, CAR-T cell’s distinctive specificity and ideal treatment outcome. Then, the three most representative limitations of CAR-T therapy are analyzed in this article: antigen escape, antigen-positive relapse, and toxicities. Finally, the article points out the promising future of CAR-T therapy.

Downloads

Download data is not yet available.

References

Ramos C A, Heslop H E, Brenner M K, et al. Car-T cell therapy for lymphoma [J]. Annual Review of Medicine, 2016, 67(1): 165–183.

Marofi F, Rahman H S, Achmad M H, et al. A deep insight into CAR-T cell therapy in Non-Hodgkin Lymphoma: Application, opportunities, and future directions [J]. Frontiers in Immunology, 2021, 12: 681984.

Zhao Z, Chen Y, Francisco N M, et al. The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges [J]. Acta Pharmaceutica Sinica B, 2018, 8(4): 539–551.

Majzner R G, Mackall C L. Tumor antigen escape from car T-cell therapy [J]. Cancer Discovery, 2018, 8(10): 1219–1226.

Sterner R C, Sterner R M. CAR-T cell therapy: Current limitations and potential strategies [J]. Blood Cancer Journal, 2021, 11(4): 69.

Cheng J, Zhao L, Zhang Y, et al. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies [J]. Frontiers in Oncology, 2019, 9: 1237.

Maude S L, Frey N, Shaw P A, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia [J]. New England Journal of Medicine, 2014, 371(16): 1507–1517.

Brudno J N, Kochenderfer J N. Recent advances in car T-cell toxicity: Mechanisms, manifestations and management [J]. Blood Reviews, 2019, 34: 45-55.

Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in car T-cell treatment for B-cell non-Hodgkin Lymphoma [J]. Signal Transduction and Targeted Therapy, 2020, 5(1).

Shah N N, Fry T J. Mechanisms of resistance to car T cell therapy [J]. Nature Reviews Clinical Oncology, 2020, 5: 134.

Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, et al. Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: Challenges and ways forward [J]. Frontiers in Immunology, 2020, 11: 702.